{"id":"NCT01313676","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease","officialTitle":"A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01-25","primaryCompletion":"2015-07-15","completion":"2015-07-15","firstPosted":"2011-03-14","resultsPosted":"2016-08-09","lastUpdate":"2018-08-06"},"enrollment":16568,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"fluticasone furoate/vilanterol","otherNames":[]},{"type":"DRUG","name":"fluticasone furoate","otherNames":[]},{"type":"DRUG","name":"vilanterol","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"fluticasone furoate/vilanterol","type":"EXPERIMENTAL"},{"label":"fluticasone furoate","type":"EXPERIMENTAL"},{"label":"vilanterol","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.","primaryOutcome":{"measure":"Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date","timeFrame":"From the date of randomization until date of death due to any cause (average of 2 study years)","effectByArm":[{"arm":"Placebo","deltaMin":275,"sd":null},{"arm":"Fluticasone Furoate 100 µg","deltaMin":251,"sd":null},{"arm":"Vilanterol 25 µg","deltaMin":265,"sd":null},{"arm":"Fluticasone Furoate/Vilanterol 100/25 µg","deltaMin":246,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.137"},{"comp":"OG000 vs OG003","p":null},{"comp":"OG000 vs OG001","p":"0.284"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":"0.655"},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG003","p":"0.681"},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":"0.299"},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":1611,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","France","Georgia","Germany","Greece","Hungary","India","Indonesia","Israel","Italy","Japan","Latvia","Malaysia","Mexico","Netherlands","North Macedonia","Philippines","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["37012070","32764918","32441114","31258919","31068182","30815468","30165984","29442524","29412688","29406772","29348179","28947039","28737971","28416587","27767328","27203508","23018908"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":918,"n":4131},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Headache","Upper respiratory tract infection","Cough"]}}